Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 11:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2809–2832 of 4,782 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple Myeloma
Interventions
Daratumumab, Lenalidomide, Bortezomib, Dexamethasone
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Rochester, New York + 1 more
Conditions
Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST, Nephroblastoma, XPO1 Gene Mutation, Solid Tumor
Interventions
Selinexor
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Months and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
16
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 13 more
Conditions
Multiple Myeloma
Interventions
Elranatamab, Standard of Care
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Ductal Carcinoma In Situ
Interventions
Granulocyte-Macrophage Colony-Stimulating Factor, Multi-epitope HER2 Peptide Vaccine H2NVAC, Therapeutic Conventional Surgery, Echocardiography Test, Biospecimen Collection, Biopsy Procedure
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Conditions
Hereditary Breast and Ovarian Cancer
Interventions
Questionnaires, Blood Draw and Baseline Questionnaire
Other
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
1,511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Stanford, California
Conditions
Solid Tumor, Hematological Malignancies
Interventions
Belinostat, Atazanavir
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Multiple Myeloma
Interventions
Lenalidomide (Revlimid), Melphalan, Dexamethasone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
New York, New York
Conditions
Relapsed Refractory Multiple Myeloma
Interventions
NEXI-002 T Cells
Biological
Lead sponsor
NexImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Duarte, California • Orlando, Florida • Boston, Massachusetts + 3 more
Conditions
Advanced Solid Tumor, BRAF Gene Mutation, BRAF Gene Alteration, MEK Mutation, MEK Alteration, MAP2K1 Gene Mutation, MAP2K1 Gene Alteration, MAP2K2 Gene Mutation, MAP2K2 Gene Alteration
Interventions
Ulixertinib, Physician's Choice
Drug
Lead sponsor
BioMed Valley Discoveries, Inc
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
22
States / cities
Phoenix, Arizona • Newport Beach, California • Newark, Delaware + 19 more
Conditions
Breast Neoplasms, Breast Cancer, Metastasis
Interventions
CAL
Drug
Lead sponsor
Chugai Pharma USA
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
38
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Concord, California + 32 more
Conditions
Lymphoma, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
MEDI-507, Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Up to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting No phase listed Observational

PumaRx Registry Trial

NCT06805461
Conditions
Solid Tumors
Interventions
RenovoCath®
Device
Lead sponsor
RenovoRx
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Coral Gables, Florida • Pittsburgh, Pennsylvania • Burlington, Vermont
Conditions
B-Cell Prolymphocytic Leukemia, Hypodiploidy, Loss of Chromosome 17p, Plasma Cell Leukemia, Progression of Multiple Myeloma or Plasma Cell Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Small Lymphocytic Lymphoma, t(14;16), t(4;14), T-Cell Prolymphocytic Leukemia, Waldenstrom Macroglobulinemia
Interventions
Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Seattle, Washington • Milwaukee, Wisconsin
Conditions
Locally Recurrent Prostate Cancer
Interventions
PRX302
Drug
Lead sponsor
Sophiris Bio Corp
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
San Antonio, Texas • Temple, Texas
Conditions
Head and Neck Cancer
Interventions
ABBV-181, ABBV-368, ABBV-927
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Tandem autologous stem cell transplant, Cisplatin, Doxorubicin, Cyclophosphamide, Etoposide, Bortezomib, Thalidomide, Melphalan
Drug · Procedure
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)

NCT05677360
Conditions
Human Papilloma Virus (HPV) Vaccine
Interventions
HPV MISTICS -Provider Level, HPV MISTICS - Parent Level, HPV MISTICS- HPV Vaccine Champion Level
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Prostate Cancer
Interventions
Standard of care ADT + (HMB + arginine + glutamine), Standard of care ADT
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
60 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Von Hippel-Lindau Disease, CNS Hemangioblastoma, Retinal Hemangioblastoma
Interventions
PTK787/ZK 222584
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
dexamethasone, pomalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Breast Neoplasms, Gastric Neoplasm, Solid Tumors
Interventions
ARX788
Drug
Lead sponsor
Ambrx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Santa Monica, California • St Louis, Missouri + 2 more
Conditions
Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mantle Cell Lymphoma
Interventions
Leuprolide acetate depot (LAD) 11.25 mg 3 Month, Matched placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
4
States / cities
St Louis, Missouri • New York, New York • Durham, North Carolina + 1 more
Conditions
Tuberous Sclerosis, Angiolipoma
Interventions
everolimus (RAD001)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
Interventions
Mesenchymal stromal cells, Placebo
Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Minneapolis, Minnesota • Pittsburgh, Pennsylvania